UK drugmaker GlaxoSmithKline has been granted a new licence for Imigran (sumatriptan succinate) RADIS, a rapidly-dissolving form of the migraine tablet Imigran for acute treatment of the condition. The new form of the drug represents the only migraine treatment proven to enable complete functional recovery after 45 minutes, and is specially formulated to be less reliant on gastric motility for disintegration, thereby overcoming the problems of gastric stasis.
Andrew Dowson, chairman of the Migraine in Primary Care Advisors Group and director of King's Headache Services, King's College London, UK, noted that "functional recovery is a key consideration when treating migraine patients and this new treatment option will allow them to overcome their attacks quickly. The problem of medication dissolution during gastric stasis has also long been an obstacle in the treatment of migraine but Imigran RADIS offers primary care teams the opportunity to tackle these two factors which are so important in the effective management of migraine."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze